PriceTargets.com logo

AbbVie - ABBV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $203.37
  • Forecasted Upside: 21.24%
  • Number of Analysts: 21
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 17 Buy Ratings
  • 1 Strong Buy Ratings
$167.74 As of 11/20/2024 01:00 AM ET
▲ +1.17 (0.70%)

This chart shows the closing price for ABBV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbbVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABBV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABBV

Analyst Price Target is $203.37
▲ +21.24% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $203.37, with a high forecast of $225.00 and a low forecast of $173.00. The average price target represents a 21.24% upside from the last price of $167.74.

This chart shows the closing price for ABBV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 21 investment analysts is to moderate buy stock in AbbVie. This rating has held steady since January 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Wells Fargo & CompanyBoost TargetBuy$195.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$205.00
11/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$210.00 ➝ $200.00
11/12/2024CitigroupLower TargetBuy ➝ Buy$226.00 ➝ $215.00
11/12/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$228.00 ➝ $208.00
11/12/2024Morgan StanleyLower TargetOverweight ➝ Overweight$231.00 ➝ $224.00
11/6/2024GuggenheimBoost TargetBuy ➝ Buy$212.00 ➝ $221.00
11/4/2024ArgusUpgradeHold ➝ Buy
10/31/2024CitigroupBoost TargetBuy ➝ Buy$215.00 ➝ $226.00
10/31/2024UBS GroupBoost TargetNeutral ➝ Neutral$195.00 ➝ $200.00
10/31/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$218.00 ➝ $231.00
10/25/2024CitigroupBoost TargetBuy ➝ Buy$170.00 ➝ $215.00
10/18/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$185.00 ➝ $195.00
10/17/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$214.00 ➝ $220.00
10/17/2024Sanford C. BernsteinInitiated CoverageMarket Perform$203.00
10/10/2024Truist FinancialBoost TargetBuy ➝ Buy$210.00 ➝ $215.00
10/9/2024UBS GroupBoost TargetNeutral ➝ Neutral$185.00 ➝ $195.00
10/7/2024BarclaysBoost TargetOverweight ➝ Overweight$200.00 ➝ $212.00
10/7/2024TD CowenBoost TargetBuy ➝ Buy$195.00 ➝ $225.00
8/30/2024William BlairUpgradeStrong-Buy
8/23/2024Piper SandlerBoost TargetOverweight ➝ Overweight$196.00 ➝ $209.00
8/12/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$211.00 ➝ $218.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
7/26/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
7/26/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$200.00 ➝ $205.00
7/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$195.00 ➝ $210.00
7/26/2024BarclaysBoost TargetOverweight ➝ Overweight$187.00 ➝ $200.00
7/19/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$180.00 ➝ $214.00
7/11/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$191.00 ➝ $196.00
7/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
7/3/2024Piper Sandler CompaniesReiterated RatingOverweight ➝ Overweight$190.00 ➝ $190.00
7/2/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$190.00 ➝ $190.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
6/18/2024Piper SandlerBoost TargetOverweight ➝ Overweight$185.00 ➝ $190.00
6/5/2024HSBCUpgradeHold ➝ Buy$185.00
5/17/2024Cantor FitzgeraldInitiated CoverageOverweight$200.00
4/29/2024BarclaysLower TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$195.00 ➝ $180.00
3/27/2024BarclaysBoost TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/22/2024GuggenheimBoost TargetBuy ➝ Buy$188.00 ➝ $190.00
2/6/2024Truist FinancialBoost TargetBuy ➝ Buy$180.00 ➝ $195.00
2/5/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$187.00 ➝ $195.00
2/5/2024BarclaysBoost TargetOverweight ➝ Overweight$175.00 ➝ $185.00
2/5/2024Raymond JamesBoost TargetOutperform ➝ Outperform$181.00 ➝ $189.00
1/29/2024William BlairUpgradeMarket Perform ➝ Outperform
1/23/2024BarclaysBoost TargetOverweight ➝ Overweight$170.00 ➝ $175.00
12/18/2023HSBCDowngradeBuy ➝ Hold$167.00 ➝ $156.00
12/11/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$173.00
12/1/2023Raymond JamesBoost TargetOutperform ➝ Outperform$177.00 ➝ $181.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$150.00
10/30/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$193.00 ➝ $196.00
10/30/2023BarclaysUpgradeEqual Weight ➝ Overweight$160.00 ➝ $170.00
10/20/2023UBS GroupLower TargetNeutral$157.00 ➝ $150.00
10/11/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$189.00 ➝ $193.00
9/28/2023Raymond JamesInitiated CoverageOutperform$177.00
7/28/2023Piper Sandler CompaniesBoost TargetOverweight$163.00 ➝ $170.00
7/28/2023Piper SandlerBoost TargetOverweight$163.00 ➝ $170.00
7/25/2023William BlairInitiated CoverageMarket Perform
7/14/2023HSBCInitiated CoverageBuy$167.00
7/12/2023Credit Suisse GroupLower Target$170.00 ➝ $160.00
4/28/2023GuggenheimLower Target$172.00 ➝ $171.00
4/28/2023Wells Fargo & CompanyLower Target$200.00 ➝ $195.00
4/12/2023BarclaysBoost Target$155.00 ➝ $160.00
4/10/2023Morgan StanleyBoost TargetOverweight$178.00 ➝ $181.00
4/5/2023ArgusDowngradeBuy ➝ Hold
2/28/2023GuggenheimInitiated CoverageBuy$172.00
2/22/2023Wolfe ResearchDowngradeOutperform ➝ Peer Perform
2/10/2023Atlantic SecuritiesLower TargetNeutral$157.00 ➝ $154.00
2/10/2023Morgan StanleyLower TargetOverweight$182.00 ➝ $178.00
2/10/2023Piper Sandler CompaniesBoost TargetOverweight$157.00 ➝ $163.00
2/10/2023Leerink PartnersUpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00
2/10/2023SVB SecuritiesUpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00
2/9/2023Piper SandlerBoost TargetOverweight$157.00 ➝ $163.00
2/6/2023BMO Capital MarketsLower TargetOutperform$169.00 ➝ $167.00
1/17/2023Piper SandlerBoost TargetOverweight$155.00 ➝ $157.00
1/5/2023Truist FinancialBoost Target$160.00 ➝ $180.00
12/6/2022Morgan StanleyBoost TargetOverweight$178.00 ➝ $182.00
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$170.00
11/8/2022Societe GeneraleDowngradeBuy ➝ Hold$155.00 ➝ $140.00
10/31/2022Atlantic SecuritiesLower TargetNeutral$162.00 ➝ $157.00
10/31/2022Morgan StanleyLower TargetOverweight$185.00 ➝ $178.00
10/31/2022BarclaysLower TargetEqual Weight$160.00 ➝ $155.00
10/31/2022BMO Capital MarketsLower TargetOutperform$170.00 ➝ $169.00
10/11/2022Morgan StanleyLower TargetOverweight$188.00 ➝ $185.00
9/30/2022Leerink PartnersLower TargetUnderperform$140.00 ➝ $135.00
8/24/2022ArgusLower TargetBuy$165.00 ➝ $155.00
8/9/2022BarclaysLower Target$160.00
8/1/2022Morgan StanleyLower TargetOverweight$191.00 ➝ $188.00
8/1/2022UBS GroupLower TargetNeutral$154.00 ➝ $146.00
8/1/2022Atlantic SecuritiesLower TargetOverweight ➝ Neutral$178.00 ➝ $162.00
7/29/2022Piper SandlerLower Target$160.00 ➝ $155.00
7/27/2022UBS GroupBoost TargetOutperform$154.00
7/8/2022Morgan StanleyBoost TargetOverweight$188.00 ➝ $191.00
5/23/2022Leerink PartnersInitiated CoverageUnderperform$140.00
5/6/2022Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$150.00
5/2/2022Wells Fargo & CompanyBoost Target$165.00 ➝ $200.00
4/25/2022BMO Capital MarketsBoost TargetOutperform$161.00 ➝ $174.00
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$122.00 ➝ $140.00
4/12/2022BarclaysBoost TargetEqual Weight$150.00 ➝ $174.00
4/6/2022Morgan StanleyBoost TargetOverweight$142.00 ➝ $192.00
3/1/2022CitigroupBoost Target$155.00 ➝ $170.00
2/28/2022UBS GroupDowngradeBuy ➝ Neutral$129.00 ➝ $147.00
2/4/2022MizuhoBoost TargetBuy$154.00 ➝ $166.00
2/3/2022JPMorgan Chase & Co.Boost Target$165.00 ➝ $180.00
2/3/2022Bank of AmericaBoost TargetNeutral$135.00 ➝ $138.00
2/3/2022The Goldman Sachs GroupBoost TargetNeutral$117.00 ➝ $122.00
2/3/2022BMO Capital MarketsBoost TargetOutperform$153.00 ➝ $154.00
2/3/2022BarclaysBoost TargetEqual Weight ➝ Equal Weight$133.00 ➝ $150.00
1/27/2022CitigroupBoost Target$125.00 ➝ $155.00
1/24/2022Morgan StanleyBoost TargetOverweight$124.00 ➝ $142.00
1/20/2022BarclaysBoost TargetEqual Weight$118.00 ➝ $133.00
1/18/2022CowenBoost Target$130.00 ➝ $150.00
1/13/2022Redburn PartnersInitiated CoverageBuy
1/12/2022BMO Capital MarketsBoost TargetOutperform$134.00 ➝ $153.00
1/5/2022MizuhoBoost TargetBuy$132.00 ➝ $154.00
1/3/2022Piper SandlerBoost Target$129.00 ➝ $160.00
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$113.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$165.00
12/7/2021BMO Capital MarketsReiterated RatingBuy$134.00
12/7/2021Leerink PartnersReiterated RatingBuy
11/24/2021Truist FinancialBoost TargetBuy$118.00 ➝ $135.00
11/23/2021Societe GeneraleUpgradeHold ➝ Buy
11/1/2021BarclaysBoost TargetEqual Weight$112.00 ➝ $118.00
11/1/2021Leerink PartnersLower TargetOutperform$142.00 ➝ $135.00
11/1/2021Morgan StanleyBoost TargetOverweight$116.00 ➝ $124.00
10/29/2021Piper SandlerBoost TargetOverweight$124.00 ➝ $129.00
9/2/2021Leerink PartnersLower TargetOutperform$148.00 ➝ $142.00
8/23/2021CowenBoost TargetOutperform$120.00 ➝ $130.00
8/20/2021Morgan StanleyReiterated RatingBuy$116.00
8/20/2021Leerink PartnersBoost TargetOutperform$145.00 ➝ $148.00
8/5/2021ArgusBoost TargetBuy ➝ Buy$130.00 ➝ $140.00
8/2/2021Leerink PartnersBoost TargetOutperform$144.00 ➝ $145.00
8/2/2021MizuhoBoost TargetBuy$128.00 ➝ $131.00
8/2/2021BarclaysBoost TargetEqual Weight$105.00 ➝ $112.00
7/27/2021Truist FinancialInitiated CoverageBuy$117.00
7/2/2021Daiwa Capital MarketsInitiated CoverageOutperform
5/3/2021BMO Capital MarketsBoost TargetOutperform$127.00 ➝ $129.00
5/3/2021MizuhoBoost TargetBuy$126.00 ➝ $128.00
4/30/2021Piper SandlerBoost TargetOverweight$120.00 ➝ $124.00
4/7/2021Royal Bank of CanadaInitiated Coverage$135.00
3/30/2021Leerink PartnersBoost TargetOutperform$140.00 ➝ $144.00
2/4/2021Leerink PartnersBoost TargetIn-Line ➝ Outperform$128.00 ➝ $140.00
2/4/2021Royal Bank of CanadaBoost TargetOutperform$129.00 ➝ $135.00
2/4/2021MizuhoBoost TargetBuy$117.00 ➝ $126.00
1/28/2021Morgan StanleyLower TargetOverweight$120.00 ➝ $116.00
12/16/2020Leerink PartnersBoost TargetOutperform$119.00 ➝ $128.00
12/15/2020MizuhoBoost Target$111.00 ➝ $117.00
11/30/2020Morgan StanleyBoost TargetPositive ➝ Overweight$108.00 ➝ $120.00
11/18/2020BMO Capital MarketsInitiated CoverageOutperform$123.00 ➝ $123.00
11/10/2020Sanford C. BernsteinInitiated CoverageOutperform$120.00
11/2/2020Leerink PartnersLower TargetOutperform$122.00 ➝ $119.00
10/23/2020Truist FinancialInitiated CoverageBuy$110.00
10/20/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$115.00 ➝ $120.00
9/29/2020Berenberg BankInitiated CoverageHold$98.00
9/27/2020MizuhoReiterated RatingBuy$111.00
9/2/2020CitigroupBoost TargetBuy$98.00 ➝ $105.00
8/20/2020Morgan StanleyBoost TargetOverweight$95.00 ➝ $108.00
8/3/2020MizuhoBoost TargetBuy$110.00 ➝ $111.00
8/3/2020Royal Bank of CanadaBoost TargetOutperform$125.00 ➝ $127.00
6/29/2020MizuhoBoost TargetTop Pick ➝ Buy$101.00 ➝ $110.00
6/25/2020Royal Bank of CanadaBoost TargetOutperform$102.00 ➝ $125.00
6/23/2020Atlantic SecuritiesUpgradeNeutral ➝ Overweight$115.00
6/18/2020Royal Bank of CanadaReiterated RatingBuy$102.00
6/17/2020UBS GroupBoost Target$96.00 ➝ $109.00
6/10/2020Evercore ISIInitiated CoverageBuy$111.00
6/10/2020Piper SandlerBoost Target$97.00 ➝ $110.00
6/9/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform
6/2/2020ArgusUpgradeHold ➝ Buy$91.40 ➝ $115.00
5/28/2020Royal Bank of CanadaReiterated RatingBuy$102.00
5/18/2020Bank of AmericaInitiated CoverageNeutral$95.00
5/12/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00
5/11/2020Morgan StanleyReiterated RatingOverweight$95.00
5/11/2020Leerink PartnersBoost TargetOutperform$107.00 ➝ $122.00
5/4/2020Leerink PartnersBoost TargetOutperform$103.00 ➝ $107.00
5/1/2020MizuhoReiterated RatingBuy$100.00
4/20/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$79.00 ➝ $93.00
4/13/2020UBS GroupLower TargetBuy$106.00 ➝ $96.00
4/12/2020Royal Bank of CanadaReiterated RatingHold$79.00
3/23/2020Societe GeneraleDowngradeBuy ➝ Hold
2/27/2020BarclaysInitiated CoverageEqual Weight$97.00 ➝ $97.00
2/18/2020CowenBoost TargetOutperform$98.00 ➝ $105.00
2/10/2020MizuhoBoost Target$96.00 ➝ $104.00
2/7/2020Piper SandlerBoost TargetOverweight$95.00 ➝ $97.00
2/5/2020MizuhoInitiated CoverageBuy$96.00 ➝ $96.00
1/23/2020Royal Bank of CanadaReiterated RatingHold$86.00
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$86.00
1/3/2020Bank of AmericaDowngradeBuy ➝ Neutral
12/26/2019CowenBoost TargetOutperform$90.00 ➝ $98.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 59 very positive mentions
  • 53 positive mentions
  • 8 negative mentions
  • 3 very negative mentions
Mentions as of
4/25/2024
  • 67 very positive mentions
  • 53 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
5/25/2024
  • 50 very positive mentions
  • 36 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/24/2024
  • 60 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 51 very positive mentions
  • 60 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 57 very positive mentions
  • 56 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
9/22/2024
  • 58 very positive mentions
  • 51 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 161 very positive mentions
  • 75 positive mentions
  • 18 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 161 very positive mentions
  • 75 positive mentions
  • 18 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $167.74
Low: $165.65
High: $167.91

50 Day Range

MA: $190.25
Low: $164.91
High: $203.87

52 Week Range

Now: $167.74
Low: $137.65
High: $207.32

Volume

7,133,346 shs

Average Volume

5,488,950 shs

Market Capitalization

$296.42 billion

P/E Ratio

58.24

Dividend Yield

3.76%

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

The following sell-side analysts have issued research reports on AbbVie in the last year: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Piper Sandler Companies, Raymond James, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for ABBV.

What is the current price target for AbbVie?

0 Wall Street analysts have set twelve-month price targets for AbbVie in the last year. Their average twelve-month price target is $203.37, suggesting a possible upside of 21.2%. TD Cowen has the highest price target set, predicting ABBV will reach $225.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $173.00 for AbbVie in the next year.
View the latest price targets for ABBV.

What is the current consensus analyst rating for AbbVie?

AbbVie currently has 3 hold ratings, 17 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABBV.

What other companies compete with AbbVie?

Other companies that are similar to AbbVie include Amgen, Gilead Sciences, Seagen, IQVIA and IDEXX Laboratories. Learn More about companies similar to AbbVie.

How do I contact AbbVie's investor relations team?

AbbVie's physical mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company's listed phone number is (847) 932-7900. The official website for AbbVie is www.abbvie.com. Learn More about contacing AbbVie investor relations.